Literature DB >> 34917312

Direct access lifestyle training improves liver biochemistry and causes weight loss but uptake is suboptimal in patients with non-alcoholic fatty liver disease.

Imran Patanwala1, Lili Emese Molnar2, Katherine Akerboom1, Katie Elizabeth Lane2.   

Abstract

OBJECTIVE: To evaluate the uptake and effectiveness of an existing open access lifestyle intervention forged in collaboration between a third sector organisation, funded by local government and a secondary care non-alcoholic fatty liver disease (NAFLD) service in the North West of England.
METHOD: A service outcome evaluation using precomparison design and postcomparison design was conducted to analyse changes between baseline clinical health records and 12-week follow-up for patients with NAFLD who completed the lifestyle intervention. Lifestyle factors, weight loss, changes in alanine aminotransferase (ALT) enzymes and lipid profiles were compared between patients who completed the programme vs 1:1 matched patients who did not.
RESULTS: Only 16 of 167 patients with NAFLD offered the intervention completed the programme. Intervention patients achieved significant weight loss (-2.3% p≤0.05) over 12 weeks, where the non-intervention group had non-significant weight gain (+0.95%). ALT improved by 20.6 IU/L in the interventional group and 15.75 IU/L in the non-intervention group; however, this was not statistically different.
CONCLUSION: This study presents first of its kind evaluation of a service collaboration in the UK. Only 1 in 10 patients offered the opportunity completed the programme, a limitation that could affect future strategies. Patient and public involvement research is needed to identify barriers to participation, address adherence issues and identify support mechanisms for lifestyle interventions in patients with NAFLD. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  fatty liver; nutritional status; nutritional support

Year:  2020        PMID: 34917312      PMCID: PMC8640420          DOI: 10.1136/flgastro-2020-101669

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  22 in total

1.  EASL Clinical Practice Guidelines: Vascular diseases of the liver.

Authors: 
Journal:  J Hepatol       Date:  2015-10-26       Impact factor: 25.083

Review 2.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

Authors:  Christian Thoma; Christopher P Day; Michael I Trenell
Journal:  J Hepatol       Date:  2011-07-01       Impact factor: 25.083

Review 3.  From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.

Authors:  J Bernadette Moore
Journal:  Proc Nutr Soc       Date:  2019-03-29       Impact factor: 6.297

Review 4.  Non-alcoholic fatty liver disease and risk of cardiovascular disease.

Authors:  Amedeo Lonardo; Silvia Sookoian; Carlos J Pirola; Giovanni Targher
Journal:  Metabolism       Date:  2015-09-25       Impact factor: 8.694

5.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Authors:  Zobair M Younossi; Vlad Ratziu; Rohit Loomba; Mary Rinella; Quentin M Anstee; Zachary Goodman; Pierre Bedossa; Andreas Geier; Susanne Beckebaum; Philip N Newsome; David Sheridan; Muhammad Y Sheikh; James Trotter; Whitfield Knapple; Eric Lawitz; Manal F Abdelmalek; Kris V Kowdley; Aldo J Montano-Loza; Jerome Boursier; Philippe Mathurin; Elisabetta Bugianesi; Giuseppe Mazzella; Antonio Olveira; Helena Cortez-Pinto; Isabel Graupera; David Orr; Lise Lotte Gluud; Jean-Francois Dufour; David Shapiro; Jason Campagna; Luna Zaru; Leigh MacConell; Reshma Shringarpure; Stephen Harrison; Arun J Sanyal
Journal:  Lancet       Date:  2019-12-05       Impact factor: 79.321

6.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

7.  Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.

Authors:  Pinar Hamurcu Varol; Eda Kaya; Emel Alphan; Yusuf Yilmaz
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-10       Impact factor: 2.566

8.  Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.

Authors:  Jessica Dyson; Bryan Jaques; Dipankar Chattopadyhay; Rajiv Lochan; Janine Graham; Debasish Das; Tahira Aslam; Imran Patanwala; Sameer Gaggar; Michael Cole; Kate Sumpter; Stephen Stewart; John Rose; Mark Hudson; Derek Manas; Helen L Reeves
Journal:  J Hepatol       Date:  2013-08-23       Impact factor: 25.083

9.  Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL).

Authors:  Pegah Golabi; Munkhzul Otgonsuren; Rebecca Cable; Sean Felix; Aaron Koenig; Mehmet Sayiner; Zobair M Younossi
Journal:  Health Qual Life Outcomes       Date:  2016-02-09       Impact factor: 3.186

10.  Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease.

Authors:  C J A Pugh; V S Sprung; H Jones; P Richardson; F Shojaee-Moradie; A M Umpleby; D J Green; N T Cable; M I Trenell; G J Kemp; D J Cuthbertson
Journal:  Int J Obes (Lond)       Date:  2016-07-21       Impact factor: 5.095

View more
  1 in total

Review 1.  Identification of liver disease: why and how.

Authors:  Iain Macpherson; Kushala W M Abeysekera; Rebecca Harris; Dina Mansour; Stuart McPherson; Ian Rowe; William Rosenberg; John F Dillon; Andrew Yeoman
Journal:  Frontline Gastroenterol       Date:  2022-01-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.